AVBP ArriVent BioPharma Inc.

$AVBP 50 million shares owned 98% tutes. No chance of getting FDA or EMA approvall. No income except for short term investments. Cash to last until sometime in 2028. Won't get them through next phase 3 trial ending in 2029. All other trials in phase 1. They'll need a cash infusion someday. Not now, but before they can hope to produce income. They only thing that could possibly save them would be putting their cash in Bitcoin and praying it hits $1,000,000. Only investors buying now are delusional. The tutes need to bail. They know it. We know it. Let them eat the loss. It's not that big split between them. This one's dead and too risky even for a swing on a delusional retail bounce.

$AVBP This will recover a bit. They have a lot of things in pipeline with $373 milion cash where it is trading after this drop

$AVBP might be worth a small enter. The trial wasn't a complete failure. Still not want they wanted though. But it did have some positives At a higher dose, patients went a median 11 months without their cancer worsening, compared with 9.5 months for chemotherapy, ArriVent BioPharma said. A lower dose resulted in median progression-free survival of 8.4 months The trial did provide some positive results. About 60% of patients receiving a higher dose of firmonertinib reported their tumors had shrunk, compared with 33% with chemotherapy.

$AVBP Back in for scalp #2 LONG for power hour. Nice bid action today off lows, buyers showed up - maybe high risk overnight if strong close

$AVBP this is a done deal, don't bait anymore retail here. trading at 2x of cash value and they need years to do anything again. This isn't at cash value of 7$ only cuz tuts need to unload the shares to retail.

$AVBP (NP) Today's biotech gut punch, down ~60% on failed phase 3 in 1L EGFR exon20 NSCLC $200M EV = perhaps a "bait & switch" opportunity when the dust clears Focus shifts to ADC programs (CDH17 in GI cancers & MUC16/NaPi2b in ovarian & endometrial) *Both via China deals

$AVBP Cash and investments: $373.1 million as of June 30, 2026.. It is trading at cash value market cap after this drop. WAY UNDERVALUED

$AVBP disappointing about firmo in exon 20 but wonder if current valuation is being driven by P3 for PACC mutations (where admittedly company has better data), and is much further along (only P3 for this indication).

$AVBP I WANNA DEFUCK NOW HOW THE POOLED MPFS WAS ONLY 9-10M YET TOPLINE WAS DELAYED ALMOST A YEAR ANSWER SHIT COMPANY SCAMMERS FFS

$AVBP Jefferies sharply cut its estimated probability of success for firmonertinib after the FURVENT Phase 3 failure: from 75% to 25% in the U.S. and from 55% to 15% in Europe. It also lowered its AVBP price target from $45 to $18, showing a major deterioration in confidence.

$AVBP $15.09 | Mixed / Sideways RSI 16.6 (Oversold) MACD Bearish | Vol 12.1x MA20 $28.39 | MA50 $29.55 MA200 $27.32 S $11.36 | R $33.99 Cap $744.05M P/E N/A | Fwd -3.8 High Volatility / High Risk | $18.86 (+25.0%)

$AVBP ArriVent's firmonertinib missed its Phase 3 in first-line lung cancer today. Shares are down 54% to about 13, on pace for the stock's worst single-day drop on record (Dow Jones). FURVENT tested the once-daily pill against chemo in previously untreated advanced NSCLC with EGFR exon 20 insertions. The higher dose gave 11 months of median progression-free survival vs 9.5 for chemo; the lower dose came in at 8.4 months, under chemo. Tumors shrank in about 60% of patients on the higher dose vs 33% on chemo. CEO Bing Yao said the results were "consistent" with earlier studies but did not show a meaningful improvement over chemo. One level down: this is not the whole franchise. The drug is already approved in China for second-line exon 20 disease (partner Allist, February), and the PACC-mutation program posted a 16.0-month median PFS in Phase 1b. Its pivotal ALPACCA Phase 3 is now enrolling. The first-line exon 20 thesis is done. PACC is the next checkpoint.

$AVBP 🚨🚨🚨 ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ $AVBP $XBI https://stocktwits.com/news/equity/markets/avbp-stock-crashes-to-all-time-low-after-lung-cancer-trial-setback/cZDtOaDRBlO

$AVBP Can someone please tell me how a stock with a billion and a half market cap and five hundred thousand shares , daily volume has a spread of about .20???